Sign up to save your podcasts
Or
Share The FDA's Gene-Therapy Reversal and the Exit of Vinay Prasad
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The FDA's Gene-Therapy Reversal and the Exit of Vinay Prasad
A top official at the Food and Drug Administration steps down after the agency changes course on a treatment for Duchenne muscular dystrophy. What does this episode say about the Trump Administration's approach toward drug development and innovation? Plus, Robert F. Kennedy Jr. says he plans to overhaul the National Vaccine Injury Compensation Program.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Paul Gigot, The Wall Street Journal
4.2
26962,696 ratings
A top official at the Food and Drug Administration steps down after the agency changes course on a treatment for Duchenne muscular dystrophy. What does this episode say about the Trump Administration's approach toward drug development and innovation? Plus, Robert F. Kennedy Jr. says he plans to overhaul the National Vaccine Injury Compensation Program.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like WSJ Opinion: Potomac Watch
View all
WSJ Tech News Briefing
1,645 Listeners
WSJ What’s News
4,322 Listeners
WSJ Your Money Briefing
1,713 Listeners
City Journal Audio
619 Listeners
The Editors
4,843 Listeners
WSJ Minute Briefing
662 Listeners
Bold Names
1,448 Listeners
Uncommon Knowledge
2,002 Listeners
The McCarthy Report
2,804 Listeners
The Journal.
5,962 Listeners
Barron's Streetwise
1,549 Listeners
Bad Bets
1,321 Listeners
WSJ Opinion: Free Expression
597 Listeners
As We Work
151 Listeners
The Charles C. W. Cooke Podcast
1,055 Listeners
WSJ's Take On the Week
126 Listeners
All Things with Kim Strassel
141 Listeners